Pfizer (NYSE:PFE) Full Year 2024 Results

Key Financial Results

• Revenue: US$63.6b (up 8.8% from FY 2023).
• Net income: US$8.02b (up 276% from FY 2023).
• Profit margin: 13% (up from 3.6% in FY 2023).
• EPS: US$1.42 (up from US$0.38 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Pfizer EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 17%.

The primary driver behind last 12 months revenue was the Global Biopharmaceuticals Business (Biopharma) segment contributing a total revenue of US$62.4b (98% of total revenue). The largest operating expense was General & Administrative costs, amounting to US$14.8b (38% of total expenses). Explore how PFE's revenue and expenses shape its earnings.

Looking ahead, revenue is expected to decline by 1.6% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 8.6%.

The company's shares are down 4.0% from a week ago.

Risk Analysis

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.